On October 16, 2023, Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status, disclosed their dealings in Allergy Therapeutics plc's securities. The form, known as Form 8.5 (EPT/RI), provides key information about the transactions. The dealings were undertaken on October 13, 2023. The form includes details of purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The purchases amounted to 20,643,462 securities at a price per unit of 0.01p, while the sales involved 83,100 securities at a price per unit ranging from 0.0135p to 0.014p.

The form does not disclose any cash-settled derivative transactions or stock-settled derivative transactions, including options. It also states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing. Additionally, there are no agreements, arrangements, or understandings relating to options or derivatives.

The contact person for this disclosure is Freddie Wooding, and the telephone number provided is +44 (0)20 7886 2969. The form concludes by stating that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.

No further information about Allergy Therapeutics or its operations is provided in this news release.